---
title: "InSilico Medicine Cayman TopCo has reached an AI-driven drug development collaboration with Eli Lilly, totaling over 100 million USD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265047900.md"
description: "InSilico Medicine Cayman TopCo has reached an AI-driven drug development collaboration with Eli Lilly worth over 100 million USD. The two parties will leverage InSilico Medicine's Pharma.AI platform technology and Eli Lilly's experience in drug development and disease research to jointly accelerate the discovery and development of innovative therapies"
datetime: "2025-11-10T01:07:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265047900.md)
  - [en](https://longbridge.com/en/news/265047900.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265047900.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/265047900.md) | [繁體中文](https://longbridge.com/zh-HK/news/265047900.md)


# InSilico Medicine Cayman TopCo has reached an AI-driven drug development collaboration with Eli Lilly, totaling over 100 million USD

InSilico Medicine Cayman TopCo, a biopharmaceutical technology company driven by generative artificial intelligence, recently reached a strategic cooperation agreement for drug research and development with Eli Lilly, a leading global multinational pharmaceutical company. Both parties will leverage the cutting-edge technological advantages of InSilico Medicine's independently developed AI pharmaceutical platform Pharma.AI, combined with Eli Lilly's deep expertise in drug development and disease research, to jointly accelerate the discovery and development of innovative therapies

### Related Stocks

- [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

- [Deals of the day-Mergers and acquisitions](https://longbridge.com/en/news/281036787.md)
- [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/en/news/281171668.md)
- [British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks](https://longbridge.com/en/news/281263193.md)
- [Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US](https://longbridge.com/en/news/281178661.md)
- [InSilico Medicine's Loss Widens in 2025; Enters Licensing Agreement With Eli Lilly](https://longbridge.com/en/news/280951810.md)